The HeartMate 3 left ventricular assist device as a strategy to bridge to transplant

ConclusionsThe HM3 is a viable method for BTT with acceptable waitlist outcomes. Although 1-year survival is comparable to primary OHT, early outcomes are worse, suggesting that refinement of patient selection and perioperative management is prudent to optimizing outcomes.

Source: Journal of Cardiac Surgery - November 2, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Maxwell F. Kilcoyne, Lauren V. Huckaby, Zubair Hashmi, Lucas Witer, Nicolas Pope, Brian A. Houston, Chakradhari Inampudi, Ryan J. Tedford, Arman Kilic Tags: ORIGINAL ARTICLE Source Type: research